Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Apr
02
Today In Oncology
Financial Hardship and Late-Stage Cancer Diagnosis
Agent Orange Exposure Linked to MDS Risk and Progression
One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia
Low-Risk Endometrial Cancer Does a Lack of Adjuvant Therapy Affect Survival
ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo